Aurora Cannabis Inc.

TSX:ACB.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$6.31 +0.48%

+$0.02 today

Market cap
$414.85M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $3.77High $9.33

Volume 0.32M

Average 0.42M

ACB.TO Sales of Investments

Cash received from selling or redeeming investments.

Aurora Cannabis Inc.TSX: ACB.TO

Sales of Investments · Q4 FY2026 · quarter ended Mar 2026

Sales of investments outflow grows to CA$0

Q4 FY2026 sales of investments was CA$0, compared with CA$0 a year earlier. Trailing-twelve-month sales of investments was CA$0.

Context

  • Sales of investments amounted to 0.0% of revenue in FY2026, down 1.6 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$0— QoQ
Last fiscal yearMar 2026
CA$0-100.0% YoY
LTMMar 2026
CA$0-100.0% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

CAD · from the cash flow

Latest · FY2026
0 CAD
Year-over-year change
-100.0%

Sales of Investments vs competitors

How ACB.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the lowest of 3, against a peer median of -0.1%.
  • Sales of investments amounts to 0.0% of revenue for ACB.TO, versus a peer median of 0.0%.
ACB.TO Competitors
Sales of Investments for ACB.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$25.95M CAD+58.0%-66.4%8.3%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$2.48M CAD-58.2%—0.9%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$0 CAD-100.0%—0.0%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$0 USD——0.0%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$0 CAD——0.0%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$0 USD——0.0%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$0 CAD——0.0%
TSND.TOTerrAscend Corp.LTM Mar 2026$0 USD——0.0%
Peer median (excluding ACB.TO) —-0.1%-66.4%0.0%

Competitors are the stored peer set for ACB.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(1.72B)(265.33M)(59.05M)15.76M(58.62M)
Depreciation & Amortization93.66M43.57M33.07M22.55M14.19M
Deferred Income Tax(2.19M)(18.4M)(1.67M)(3.19M)55K
Stock-Based Compensation13.76M16.89M12.72M11.52M7.29M
Change in Working Capital52.65M(25.12M)(15.63M)10.21M(9.21M)
Accounts Receivables18.34M5.53M(4.33M)5.24M(8.15M)
Inventory21.07M49.03M3.62M(15.05M)7.44M
Accounts Payables6.77M(8.06M)(15.7M)14.91M(8.04M)
Other Working Capital6.48M(71.61M)790K5.11M(9.21M)
Other Non-Cash Items1.45B190.11M(37.96M)(40.85M)54.32M
Operating Cash Flow(110.27M)(115.82M)(68.51M)16.01M(13.51M)
Capital Expenditures(32.21M)(12.13M)(16.96M)(18.86M)(22.55M)
Acquisitions (Net)(23.42M)(18.54M)(5.55M)01.1M
Purchases of Investments00000
Sales of Investments03.36M4.99M5.49M0
Other Investing Activities19.46M16K12.02M(956K)(51.98M)
Investing Cash Flow(36.17M)(27.29M)(5.49M)(14.33M)(73.43M)
Debt Repayment(170.83M)—(85.76M)(805K)(5.02M)
Common Stock Issued350.19M73.19M37.93M00
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(31.58M)(95.21M)(89K)689K(154K)
Financing Cash Flow147.78M(56.48M)(47.92M)(116K)9.76M
Effect of Forex Changes15.01M15.54M297K264K4.33M
Net Change in Cash16.35M(140.01M)(121.5M)1.83M(72.85M)
Free Cash Flow(142.48M)(127.95M)(85.46M)(2.85M)(36.06M)

Aurora Cannabis Inc.

TSX:ACB.TO

Intrinsic Alpha fair value

Locked

Current Price

$6.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.